A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage ...

BISMARCK, N.D. (North Dakota Monitor) – The North Dakota House of Representatives voted 59-27 on Thursday for a bill to lower ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...

Recent health news highlights controversial language restrictions within the FDA, legal actions against vape distributors in ...

Dr. Mehmet Oz, nominated to run the Centers for Medicare & Medicaid Services, will sell shares in Eli Lilly and UnitedHealth.

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Veradigm will add four new directors to its board in an agreement with investor Kent Lake Capital, the healthcare technology company said on Thursday just weeks after concluding a strategic review.

At the time of writing in mid-February, Grayscale Bitcoin Trust ETF (ticker: GBTC) is the ETF with the highest 10-year return. The ETF has produced an annualized daily return of 78.74% (by net asset ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...